Tiny study tracks heart Drug's journey in healthy men
NCT ID NCT07656779
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This early-stage study will give a small dose of a radioactive-labeled drug called HRS-1893 to 6 healthy men. Researchers will track how the drug is absorbed, broken down, and eliminated through urine and feces. The goal is to understand the drug's path in the body, which is a key step before testing it as a treatment for heart muscle diseases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangnan University Affiliated Hospital
Wuxi, Jiangsu, 214100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-1893 (a radioactive-labeled drug)
What this could lead to
If successful, this study will help researchers understand how HRS-1893 is processed and eliminated by the body, guiding future trials for heart muscle diseases.
What could go wrong
This is a very early Phase 1 study with only 6 healthy volunteers, not patients. It focuses on basic drug behavior, not treatment effects, so it may not lead to a therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.